NasdaqCM:ABEOBiotechs
Abeona Therapeutics (ABEO) Is Up 17.9% After ZEVASKYN Wins Permanent J-Code and Narrows Net Loss – Has The Bull Case Changed?
Abeona Therapeutics recently reported a third-quarter 2025 net loss of US$5.16 million, a significant improvement from US$30.27 million a year earlier, as its efforts to commercialize ZEVASKYN for RDEB patients advance alongside expanded treatment center access.
A pivotal development includes the Centers for Medicare and Medicaid Services establishing a permanent J-code for ZEVASKYN, poised to support broader reimbursement and access from January 2026.
With a 17.90% weekly and 18.47% daily...